NasdaqGS:COLLPharmaceuticals
Why Collegium Pharmaceutical (COLL) Is Up 14.1% After Surging Q3 Profits and Raised 2025 Revenue Guidance
Collegium Pharmaceutical, Inc. reported that for the third quarter ended September 30, 2025, net income rose to US$31.51 million from US$9.34 million a year earlier, and raised full-year 2025 net product revenue guidance to US$775–785 million.
This combination of substantially higher quarterly profits and increased revenue projections provides an updated view of the company's financial momentum and outlook.
Given the boost in quarterly earnings and upgraded revenue guidance, we'll assess how...